Home › Intelligence › Flash

Lycia Therapeutics Files Amended S-1 Registration Statement with SEC

Flash2026-10-20

Lycia Therapeutics, Inc. filed an amended S-1 registration statement (AccNo: 0001628280-26-066381, 15 MB) with the SEC on October 20, 2026, advancing its planned NASDAQ IPO. As a clinical-stage biotech developing targeted protein degradation therapies, the filing reflects progress through SEC review cycles and disclosure refinement.

51CFO view：For biotech IPOs, the CFO must own S-1 financial statements, MD&A, and accounting policy disclosures — especially R&D expense capitalization, stock-based compensation, and clinical trial accruals. The large filing size signals multiple SEC comment rounds, demanding deep SEC reporting experience and rapid response capability.

Lycia Therapeutics, Inc. filed an amended S-1 registration statement (AccNo: 0001628280-26-066381, 15 MB) with the SEC on October 20, 2026, advancing its planned NASDAQ IPO. As a clinical-stage biotech developing targeted protein degradation therapies, the filing reflects progress through SEC review cycles and disclosure refinement.

Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search

Where this touches your finance hire

Every listing event changes what you need from a CFO. Start from the step you are actually at.

Who owns SEC reporting and US GAAP? Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments. Read → What kind of CFO does a US IPO need? S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements. Read → Who runs finance through a SPAC merger? De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ. Read →
‹ Actuate Therapeutics Files Amended S-1/A Ahead of IPO
Anonymous Company Files S-1 Registration Statement to Launch U.S. IPO Process ›